Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Plasma drug level validates self-reported adherence but predicts limited specificity for nonadherence to antiretroviral therapy.

Balikuddembe R, Kayiwa J, Musoke D, Ntale M, Baveewo S, Waako P, Obua C.

ISRN Pharmacol. 2012;2012:274978. doi: 10.5402/2012/274978. Epub 2012 Mar 6.

2.

Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.

Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J; Leishmaniasis East Africa Platform (LEAP) group.

PLoS Negl Trop Dis. 2010 Oct 26;4(10):e709. doi: 10.1371/journal.pntd.0000709.

3.

Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators.

Ross-Degnan D, Pierre-Jacques M, Zhang F, Tadeg H, Gitau L, Ntaganira J, Balikuddembe R, Chalker J, Wagner AK; INRUD IAA.

BMC Health Serv Res. 2010 Feb 19;10:42. doi: 10.1186/1472-6963-10-42.

4.

Acid burns from personal assault in Uganda.

Asaria J, Kobusingye OC, Khingi BA, Balikuddembe R, Gomez M, Beveridge M.

Burns. 2004 Feb;30(1):78-81.

PMID:
14693090

Supplemental Content

Loading ...
Support Center